Search
Aclaris Therapeutics Inc
ACRSAdd to Watchlist
3.920USD
-0.080-2.00%
Close 11-13 16:00（ET）
578.63MMarket Cap
LossP/E TTM
Aclaris Therapeutics Inc (ACRS) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Aclaris Therapeutics Inc in the past month.
Buy
6 Strong Buy
6 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
10.125USD+155.04%
ACRS Analyst Recommendation Trends
In the current month, ACRS has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ACRS average Analyst price target in the last month is 10.125.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
6
6
6
6
6
5
4
4
6
6
5
5
4
4
4
4
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
12
12
11
10
9
9
ACRS Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, ACRS EPS is projected to reach -0.173 in FY2026Q4, following reported EPS of -0.124 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.16
-0.16
-0.16
-0.17
-0.18
Actual
-0.15
-0.15
-0.12
--
--
Surprise
+2.46%
+5.84%
+24.73%
--
--
FAQs
What is Aclaris Therapeutics Inc's expected revenue for the next quarter?
Aclaris Therapeutics Inc's expected revenue is 1.27M.
What is Aclaris Therapeutics Inc's price target?
Analysts forecast that Aclaris Therapeutics Inc's price target is USD 10.12, with the highest forecast at USD 16.00 and the lowest forecast at USD 4.00.
How have Aclaris Therapeutics IncACRS's recent earnings per share performed?
The market expectation was USD -0.12, while Aclaris Therapeutics IncACRS's earnings per share (EPS) for the previous quarter was USD -0.15. EPS for the next quarter is expected at USD -0.17.
What is the analyst rating for Aclaris Therapeutics Inc?
Based on the ratings of Aclaris Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.